T-DXd作为胃/胃食管交界癌的二线治疗有效。 - Suppr | 超能文献

T-DXd effective as second-line therapy in G/GEJ cancers.

作者信息

Sidaway Peter

机构信息

Nature Reviews Clinical Oncology, .

出版信息

Nat Rev Clin Oncol. 2025 Aug;22(8):544. doi: 10.1038/s41571-025-01044-8.

DOI:10.1038/s41571-025-01044-8

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

T-DXd effective as second-line therapy in G/GEJ cancers.

Nat Rev Clin Oncol. 2025 Aug;22(8):544. doi: 10.1038/s41571-025-01044-8.

2

Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric Cancer.

JCO Precis Oncol. 2024 May;8:e2300681. doi: 10.1200/PO.23.00681.

3

Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody-drug conjugate development.

Gastric Cancer. 2025 May;28(3):422-441. doi: 10.1007/s10120-025-01584-z. Epub 2025 Feb 7.

4

Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report.

Am J Case Rep. 2022 Mar 4;23:e935600. doi: 10.12659/AJCR.935600.

5

A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.

Dis Model Mech. 2019 Dec 17;12(12):dmm041004. doi: 10.1242/dmm.041004.

6

Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.

ESMO Open. 2025 Jun 17;10(7):105330. doi: 10.1016/j.esmoop.2025.105330.

7

Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).

Gastric Cancer. 2025 Jan;28(1):51-61. doi: 10.1007/s10120-024-01555-w. Epub 2024 Oct 10.

8

Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments.

AAPS J. 2025 Jun 4;27(4):106. doi: 10.1208/s12248-025-01087-w.

9

Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.

Adv Ther. 2025 May;42(5):2015-2018. doi: 10.1007/s12325-024-03080-9. Epub 2025 Mar 6.

10

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.

J Cancer Res Clin Oncol. 2023 Dec;149(20):17933-17942. doi: 10.1007/s00432-023-05496-2. Epub 2023 Nov 14.

本文引用的文献

1

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.

N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119. Epub 2025 May 31.